Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023 16:05 ET
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Progressing as Planned with Nearly 30 Sites Now Open - - Proprietary Suprachoroidal Injection Platform Featured in Peer-Reviewed Publication and at ARVO,...
Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings
July 20, 2023 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 20, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Global Nonmydriatic Handheld Fundus Cameras Strategic Business Report 2023: Rise of AI-Powered Non-Mydriatic Handheld Devices Drives Growth
July 19, 2023 04:28 ET
|
Research and Markets
Dublin, July 19, 2023 (GLOBE NEWSWIRE) -- The "Nonmydriatic Handheld Fundus Cameras: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market...
Clearside Biomedical Announces Enrollment of Multiple Participants in its ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
July 17, 2023 07:05 ET
|
Clearside Biomedical, Inc.
- Evaluating CLS-AX as a Potential Twice-a-Year Therapy - - Trial Progressing with Topline Results Expected in Q3 2024 - ALPHARETTA, Ga., July 17, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical,...
Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema
July 10, 2023 07:05 ET
|
Clearside Biomedical, Inc.
- XIPERE® is referred to as Arcatus (ARVN001) by Arctic Vision – ALPHARETTA, Ga., July 10, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company...
AI-Based Health Screening Company iHealthScreen Reaches $150K in Investments
June 26, 2023 20:25 ET
|
iHealthScreen Inc.
RICHMOND HILL, N.Y., June 26, 2023 (GLOBE NEWSWIRE) -- AI-based health screening company iHealthScreen recently announced raising $150,000 in investments on StartEngine. To date, the company has...
Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
June 01, 2023 07:05 ET
|
Clearside Biomedical, Inc.
- U.S. Clinical Sites Screening Treatment-Experienced Participants with Wet AMD - - ODYSSEY Topline Results Expected in Q3 2024 - ALPHARETTA, Ga., June 01, 2023 (GLOBE NEWSWIRE) --...
Clearside Biomedical to Participate in a Fireside Chat at the JMP Securities Life Sciences Conference
May 09, 2023 16:30 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 09, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Global Macular Degeneration Treatment Market Report 2023: Major Players Include Novartis, Bausch Health Companies, Regenxbio, F Hoffmann-La Roche and Regeneron Pharmaceuticals
March 23, 2023 11:03 ET
|
Research and Markets
Dublin, March 23, 2023 (GLOBE NEWSWIRE) -- The "Macular Degeneration Treatment Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides...
Global Retinal Disorder Treatment Market Report 2023 to 2030: Increasing Prevalence of Target Diseases Drives Growth
March 14, 2023 12:18 ET
|
Research and Markets
Dublin, March 14, 2023 (GLOBE NEWSWIRE) -- The "Retinal Disorder Treatment Market Size, Share & Trends Analysis Report By Type (Macular Degeneration, Diabetic Retinopathy), By Dosage Form, By...